Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 180-188 , March 2010

Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines

  • Hervé Wallerand, M.D., Ph.D.

      Affiliations

    • Department of Urology, CHU Pellegrin, Victor Segalen School of Medicine, Bordeaux, France
    • Department of Urology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    • Inserm, CHU Mondor, Créteil, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 5 56 79 55 35; fax: +33 5 56 79 56 51
    • ,
  • Ying Cai, Ph.D.

      Affiliations

    • Department of Urology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    • ,
  • Zev A. Wainberg, M.D.

      Affiliations

    • Department of Urology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    • ,
  • Isla Garraway, M.D., Ph.D.

      Affiliations

    • Department of Urology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    • ,
  • Isabelle Lascombe, Ph.D.

      Affiliations

    • Department of Urology, CHU Saint-Jacques, Besançon, France
    • ,
  • Gaëlle Nicolle, Ph.D.

      Affiliations

    • Inserm, CHU Mondor, Créteil, France
    • ,
  • Jean-Paul Thiery, M.D., Ph.D.

      Affiliations

    • Curie Institute, Paris, France
    • ,
  • Hugues Bittard, M.D., Ph.D.

      Affiliations

    • Department of Urology, CHU Saint-Jacques, Besançon, France
    • ,
  • François Radvanyi, Ph.D.

      Affiliations

    • Curie Institute, Paris, France
    • ,
  • Robert R. Reiter, M.D., Ph.D.

      Affiliations

    • Department of Urology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA

Received 18 June 2008 ,Revised 29 August 2008 ,Accepted 30 September 2008.

References 

  1. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–675
  2. Yang J, Mani SA, Weinberg RA. Exploring a new twist on tumor metastasis. Cancer Res. 2006;66:4549–4552
  3. Hazan RB, Kang L, Whooley BP, et al. N-cadherin promotes adhesion between invasive breast cancer cells and the stroma. Cell Adhesion Commun. 1997;4:399–411
  4. Hazan RB, Phillips GR, Qiao RF, et al. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 2000;148:779–790
  5. Hazan RB, Qiao R, Keren R, et al. cadherin switch in tumor progression. Ann NY Acad Sci. 2004;1014:155–163
  6. Clairotte A, Lascombe I, Fauconnet S, et al. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: Identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol. 2006;125:119–126
  7. Imao T, Koshida K, Endo Y, et al. Dominant role of E-cadherin in the progression of bladder cancer. J Urol. 1999;161:692–698
  8. Popov Z, Gil-Diez de Medina S, Lefrere-Belda MA, et al. Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br J Cancer. 2000;83:209–214
  9. Rieger-Christ KM, Cain JW, Brasch JW, et al. Expression of classic cadherins type I in urothelial neoplastic progression. Hum Pathol. 2001;32:18–23
  10. Perl AK, Wilgenbus P, Dahl U, et al. Causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998;392:190–193
  11. Missing EM, Bubbers JE, DeKernion JB, et al. Growth stimulating activity produced by human bladder cancer cells. J Urol. 1984;132:1230–1234
  12. Theodorescu D, Comil I, Sheehan C, et al. Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factors receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Cancer Res. 1991;51:4486–4491
  13. Rieger-Christ KM, Lee P, Zagha R, et al. Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway. Oncogene. 2004;23:4745–4753
  14. Nicolle G, Daher A, Maillé P, et al. Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. Clin Cancer Res. 2006;12:2937–2943
  15. Irie HY, Pearline RV, Grueneberg D, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol. 2005;171:1023–1034
  16. Toker A, Yoeli-Lerner M. Akt signaling and cancer: Surviving but not moving on. Cancer Res. 2006;66:3963–3966
  17. Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006;66:944–950
  18. Baumgart E, Cohen MS, Neto BS, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res. 2007;13:1685–1694
  19. Lascombe I, Clairotte A, Fauconnet S, et al. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res. 2006;12:780–787
  20. Stewart DJ. Final clinical and pharmacokinetic (PK) results from a phase I study of the novel N-cadherin antagonist, Exegerin (ADH-1) in patients with refractory solid tumors stratified according to N-cad expression 2006. Proceedings of the ASCO meeting, Atlanta, GA, June 2006.

☆ This article is specifically dedicated to the memory of Professor Dominique K. Chopin.

PII: S1078-1439(08)00258-5

doi: 10.1016/j.urolonc.2008.09.041

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 180-188 , March 2010

Article Tools

* Image Usage & Resolution